AUG 30, 2016 08:00 AM PDT

Transitioning to the clinic from proof of concept research: Challenges associated with converting research materials and methods to a clinical grade product

Speakers
  • Team Leader, Processing/Manufacturing, Heart Regeneration Program, University of Washington School of Medicine, United States
    Biography
      Ben Fryer is the team leader for CMC-Cell Manufacturing and Processing at the University of Washington School of Medicine's Heart Regeneration Program (HRP). Ben joined the HRP in January 2015. The program was started by Chuck Murry and is currently in pre-clinical development of a therapy to treat heart disease using cardiomyocytes generated from hES cells.

      Prior to joining HRP, Ben worked at Janssen R&D's internal diabetes venture (BetaLogics) from 2006 to 2014. BetaLogics' mission was to treat insulin-dependent diabetes with a combination islet-like tissue product generated from hES cells and delivered via an immune-isolation device. Ben managed an internal research team and several external partnerships dedicated to finding a defined and scalable method to manufacture pancreatic beta islets for the treatment and cure of diabetes.

      Ben earned a BA from Colorado College and his PhD in pharmacology from the University of Pennsylvania. As a post-doc he studied Hypoxia Inducible Factor in cancer and stem cell development in the Howard Hughes Laboratory of M. Celeste Simon at the University of Pennsylvania. Prior to graduate school he worked for several small biotech/pharmaceutical firms in the Denver-Boulder area supporting discovery research and pre-clinical and clinical development of small and large molecule therapies for cancer.

      Ben is an inventor on several pending patents for Janssen/Johnson&Johnson, including stirred tank bioreactor based suspension expansion and differentiation processes and a product currently marketed by Thermo-Fisher™ as Nunc™ Nunclon™Vita.

    Abstract:
    Years of significant effort can go into generating key proof of concept data to support moving bench research to clinical development.Yet, much work remains in order to transition from POC to clinical trials for a cell therapy. Raw materials, processes, and cell banks may all require changes to meet regulatory guidances and more stringent specifications for treating a patient. We will discuss the practical aspects of developing a cell therapy to treat heart disease.
     

    Show Resources
    You May Also Like
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    JUN 19, 2019 10:00 AM PDT
    JUN 19, 2019 10:00 AM PDT
    DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
    NOV 18, 2019 07:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    NOV 18, 2019 07:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
    Loading Comments...
    Show Resources
    Attendees